Barry Flannelly - Incyte President

INCY Stock  USD 56.97  0.15  0.26%   

President

Mr. Barry P. Flannelly is Executive Vice President and General Manager US of Incyte Corporationrationration. He has served as Executive Vice President and General Manager US since June 2015 and joined Incyte as Executive Vice President, Business Development and Strategic Planning in August 2014. Prior to joining Incyte, he served as Chief Executive Officer of OSS Healthcare Inc., a biotechnology startup company, from August 2013 to July 2014. He served as Vice President, Global Product Strategy and Commercial Planning of Nektar Therapeutics, a biopharmaceutical company, from April 2011 until April 2013, and as Senior Vice President, Commercial, of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from August 2008 until January 2011. Prior thereto, Dr. Flannelly held key positions at biopharmaceutical and pharmaceutical companies such as Abraxis BioScience, Inc. and Novartis since 2015.
Age 60
Tenure 9 years
Address 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Phone302 498 6700
Webhttps://www.incyte.com
Flannelly earned his doctorate in pharmacy from the University of Maryland, School of Pharmacy, his master’s degree in business administration from the University of Baltimore, and his B.S. degree in Pharmacy from Massachusetts College of Pharmacy.

Incyte Management Efficiency

The company has return on total asset (ROA) of 0.0646 % which means that it generated a profit of $0.0646 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.125 %, meaning that it created $0.125 on every $100 dollars invested by stockholders. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024. Return On Assets is likely to rise to 0.09 in 2024. At this time, Incyte's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2.2 B in 2024, whereas Intangible Assets are likely to drop slightly above 74.2 M in 2024.
The company currently holds 38.29 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Incyte has a current ratio of 3.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Incyte until it has trouble settling it off, either with new capital or with free cash flow. So, Incyte's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Incyte sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Incyte to invest in growth at high rates of return. When we think about Incyte's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 13 records

PRESIDENT Age

Howard LeinerVericel Corp Ord
N/A
Athena KartsaklisVBI Vaccines
59
Rebeccah BrownMiMedx Group
N/A
Edward BorkowskiMiMedx Group
58
Randall SpencerMiMedx Group
N/A
Gerard MichelVericel Corp Ord
54
William TaylorMiMedx Group
47
Frank BurrowsMiMedx Group
N/A
Adam MDMIRA Pharmaceuticals Common
57
Robert MDMiMedx Group
73
Adam BuckleyVBI Vaccines
48
John HarrisMiMedx Group
N/A
Mark LandyMiMedx Group
51
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. Incyte Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 2094 people. Incyte (INCY) is traded on NASDAQ Exchange in USA. It is located in 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803 and employs 2,524 people. Incyte is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Incyte Leadership Team

Elected by the shareholders, the Incyte's board of directors comprises two types of representatives: Incyte inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incyte. The board's role is to monitor Incyte's management team and ensure that shareholders' interests are well served. Incyte's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incyte's outside directors are responsible for providing unbiased perspectives on the board's policies.
Steven Stein, Senior Vice President and Chief Medical Officer
Paul Trower, Principal Accounting Officer and VP of Fin.
Thomas Tray, Chief Finance
Pamela Murphy, Vice Communications
Eric Siegel, Executive Vice President General Counsel
Vijay Iyengar, Executive Vice President Global Strategy and Corporate Development`
Reid Huber, Chief Scientific Officer and Executive VP
Richard Levy, Executive Vice President Chief Drug Development and Medical Officer
Christine Chiou, Head Relations
PharmD MBA, Executive America
JeanJacques Bienaime, Independent Director
Paul Brooke, Independent Director
Maria Pasquale, Executive Vice President General Counsel
Christiana Stamoulis, CFO, Executive Vice President
Steven MD, Executive Officer
Julian Baker, Independent Vice Chairman of the Board
Sheila Denton, Executive Counsel
Michael Booth, VP - Investor Relations
David Gryska, CFO, Executive Vice President
Paul Friedman, Director
Wenqing Yao, Executive Vice President - Discovery Medicinal and Process Chemistry
Jacqualyn Fouse, Director
Paula Swain, Executive Resources
Paul Clancy, Director
Wendy Dixon, Independent Director
Michael Morrissey, Executive Operations
Herve Hoppenot, Chairman, CEO and President and Member of Non-Management Stock Option Committee
Barry Flannelly, Executive Vice President - Business Development and Strategic Planning
Dashyant Dhanak, Executive Vice President Chief Scientific Officer
Christiana MBA, Executive CFO
Maria JD, Gen VP
MBA MBA, Ex America

Incyte Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incyte a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Incyte Investors Sentiment

The influence of Incyte's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Incyte. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Incyte's public news can be used to forecast risks associated with an investment in Incyte. The trend in average sentiment can be used to explain how an investor holding Incyte can time the market purely based on public headlines and social activities around Incyte. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Incyte's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Incyte's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Incyte's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Incyte.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Incyte in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Incyte's short interest history, or implied volatility extrapolated from Incyte options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Incyte offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Incyte's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Incyte Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Incyte Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Incyte Stock please use our How to Invest in Incyte guide.
Note that the Incyte information on this page should be used as a complementary analysis to other Incyte's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Complementary Tools for Incyte Stock analysis

When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
CEOs Directory
Screen CEOs from public companies around the world
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Is Incyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incyte. If investors know Incyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.324
Earnings Share
2.65
Revenue Per Share
16.526
Quarterly Revenue Growth
0.093
Return On Assets
0.0646
The market value of Incyte is measured differently than its book value, which is the value of Incyte that is recorded on the company's balance sheet. Investors also form their own opinion of Incyte's value that differs from its market value or its book value, called intrinsic value, which is Incyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incyte's market value can be influenced by many factors that don't directly affect Incyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.